Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 16,200 shares, a decrease of 47.9% from the October 31st total of 31,100 shares. Based on an average trading volume of 1,620,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.0% of the company’s shares are short sold.

Insiders Place Their Bets

In other news, major shareholder Co. Ltd. Dgp bought 237,223 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was acquired at an average cost of $3.00 per share, with a total value of $711,669.00. Following the transaction, the insider now directly owns 849,223 shares in the company, valued at approximately $2,547,669. This trade represents a 38.76 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 3.90% of the company’s stock.

Exicure Price Performance

Shares of Exicure stock opened at $29.49 on Friday. The stock has a market cap of $63.99 million, a price-to-earnings ratio of -14.25 and a beta of 1.28. The firm’s 50-day moving average is $6.26 and its two-hundred day moving average is $2.64. Exicure has a 1 year low of $1.44 and a 1 year high of $36.00.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.